BidaskClub upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a hold rating to a buy rating in a report released on Monday.
Several other brokerages also recently commented on ABEO. HC Wainwright reissued a buy rating and issued a $30.00 price target on shares of Abeona Therapeutics in a report on Friday, April 20th. Cantor Fitzgerald reissued a buy rating and issued a $36.00 price target on shares of Abeona Therapeutics in a report on Wednesday, May 16th. SunTrust Banks cut their price target on shares of Abeona Therapeutics to $23.00 and set a positive rating for the company in a report on Wednesday, May 16th. Maxim Group set a $35.00 price target on shares of Abeona Therapeutics and gave the company a buy rating in a report on Monday, May 14th. Finally, ValuEngine raised shares of Abeona Therapeutics from a hold rating to a buy rating in a report on Friday, June 1st. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Abeona Therapeutics presently has a consensus rating of Buy and an average price target of $28.56.
Abeona Therapeutics opened at $16.55 on Monday, according to Marketbeat. The company has a market capitalization of $752.15 million, a P/E ratio of -25.08 and a beta of 1.27. Abeona Therapeutics has a 12 month low of $4.85 and a 12 month high of $22.75.
Several institutional investors have recently bought and sold shares of the company. Millennium Management LLC raised its position in shares of Abeona Therapeutics by 2,357.3% during the 1st quarter. Millennium Management LLC now owns 916,256 shares of the biopharmaceutical company’s stock valued at $13,148,000 after buying an additional 878,969 shares in the last quarter. Nexthera Capital LP purchased a new position in Abeona Therapeutics in the 1st quarter worth $5,302,000. Sabby Management LLC purchased a new position in Abeona Therapeutics in the 1st quarter worth $187,000. UBS Group AG raised its position in Abeona Therapeutics by 36.5% in the 1st quarter. UBS Group AG now owns 152,081 shares of the biopharmaceutical company’s stock worth $2,182,000 after purchasing an additional 40,680 shares during the period. Finally, Knott David M purchased a new position in Abeona Therapeutics in the 1st quarter worth $101,000. Hedge funds and other institutional investors own 69.11% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.